Kristo Gentian, Yoshimura Yukihiro, Ferraris Suellen P, Jahania Salik A, Mentzer Robert M, Lasley Robert D
Department of Surgery, University of Kentucky, College of Medicine, Lexington, KY 40536-0084, USA.
J Am Coll Surg. 2004 Oct;199(4):586-94. doi: 10.1016/j.jamcollsurg.2004.05.274.
We tested whether the combination of two known cardioprotective agents, the type-1 sodium-hydrogen exchanger inhibitor cariporide plus the adenosine A(1)/A(2a) receptor agonist AMP579 ([1S-[1a,2b,3b, 4a(S*)]]-4-[7-[[2-(3-chloro-2-thienyl)-1-methylpropyl]amino]-[(3)H]-imidazo[4,5-b]pyridyl-3-yl]cyclopentane carboxamide), acted additively to reduce myocardial infarct size.
Pigs underwent 1 hour of coronary artery occlusion and 3 hours reperfusion. Vehicle-treated controls were compared with animals treated before ischemia with low-dose and high-dose cariporide and AMP579, and low-dose cariporide plus AMP579. The effects of both agents, alone and in combination, were also tested in isolated porcine polymorphonuclear neutrophils (PMNs). The PMN respiratory burst was induced with phorbol 12-myristate 13-acetate and quantified by the increase in 2',7'-dichlorofluorescein fluorescence, measured by flow cytometry.
Infarct size in the control pigs was 65 +/- 1% of the area at risk. Cariporide dose-dependently reduced infarct size to 39 +/- 2% and 24 +/- 3% in the low- and high-dose groups, respectively. Infarct size was 54 +/- 3% in the low-dose AMP579 group and 47 +/- 3% with high dose. The combination of low doses of cariporide and AMP579 reduced infarction to 25 +/- 6% of the area at risk. In the PMN studies, cariporide and AMP579 alone had no effect on 2',7'-dichlorofluorescein fluorescence, but the combination of the two agents reduced the PMN 2',7'-dichlorofluorescein increase to 79 +/- 5% of the vehicle control response.
The preischemic combination of low doses of cariporide and AMP579 decreased myocardial infarct size more than either agent used alone in low concentration, indicating an additive effect of the two agents. Given the effects that cariporide plus AMP579 combination exerted on PMN activity, it appears that this combination has the potential to reduce PMN-mediated effects during myocardial reperfusion.
我们测试了两种已知的心脏保护剂,即1型钠氢交换体抑制剂卡立泊来德与腺苷A(1)/A(2a)受体激动剂AMP579([1S-[1a,2b,3b,4a(S*)]-4-[7-[[2-(3-氯-2-噻吩基)-1-甲基丙基]氨基]-[(3)H]-咪唑并[4,5-b]吡啶基-3-基]环戊烷甲酰胺)联合使用是否具有相加作用以缩小心肌梗死面积。
猪经历1小时冠状动脉闭塞和3小时再灌注。将用赋形剂处理的对照组与在缺血前用低剂量和高剂量卡立泊来德及AMP579以及低剂量卡立泊来德加AMP579处理的动物进行比较。还在分离的猪多形核中性粒细胞(PMN)中测试了两种药物单独及联合使用的效果。用佛波酯12-肉豆蔻酸酯13-乙酸酯诱导PMN呼吸爆发,并通过流式细胞术测量2',7'-二氯荧光素荧光的增加进行定量。
对照猪的梗死面积为危险区面积的65±1%。卡立泊来德剂量依赖性地将梗死面积分别降低至低剂量组的39±2%和高剂量组的24±3%。低剂量AMP579组的梗死面积为54±3%,高剂量组为47±3%。低剂量卡立泊来德和AMP579联合使用将梗死面积降低至危险区面积的25±6%。在PMN研究中,单独的卡立泊来德和AMP579对2',7'-二氯荧光素荧光无影响,但两种药物联合使用将PMN 2',7'-二氯荧光素的增加降低至赋形剂对照反应的79±5%。
缺血前低剂量卡立泊来德和AMP579联合使用比单独使用低浓度的任何一种药物更能减少心肌梗死面积,表明两种药物具有相加作用。鉴于卡立泊来德加AMP579联合使用对PMN活性的影响,似乎这种联合用药有可能减少心肌再灌注期间PMN介导的效应。